febuxostat has been researched along with Fatty Liver, Nonalcoholic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, M; Fukuoka, T; Hirohata, S; Honma, K; Kakimoto, M; Kirihara, S; Kitamori, K; Nakayama, H; Ran, S; Sato, I; Watanabe, S; Yamamoto, S | 1 |
| Asano, T; Fujishiro, M; Fukushima, T; Kamata, H; Kanaoka, R; Katasako, A; Kushiyama, A; Matsunaga, Y; Mori, K; Nakatsu, Y; Sakoda, H; Seno, Y; Yamamotoya, T | 1 |
2 other study(ies) available for febuxostat and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats.
Topics: Animals; Antioxidants; Atherosclerosis; Diet, High-Fat; Enzyme Inhibitors; Febuxostat; Lipids; Non-alcoholic Fatty Liver Disease; Rats; Rats, Inbred SHR; Uric Acid; Xanthine Oxidase | 2023 |
The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Topics: Animals; Apoptosis; Choline Deficiency; Cytoprotection; Diet, High-Fat; Enzyme Inhibitors; Febuxostat; Gout Suppressants; Hyperuricemia; Liver; Liver Cirrhosis, Experimental; Methionine; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Thiazoles; Uric Acid; Xanthine Oxidase | 2015 |